AiTan (rivoceranib) / Jiangsu Hengrui Pharma, HLB Bio Group, Bukwang Pharma, Advenchen - LARVOL DELTA

Apatinib Reverses Tamoxifen Resistance in ER+ Breast Cancer via the VEGFR2/ERα/PI3K/Akt Pathway (ESMO 2025) - No abstract available

Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • KDR

Adebrelimab Plus Apatinib in Advanced Esophageal Squamous Cell Carcinoma Following Immune Checkpoint Inhibitors: Preliminary Results from Cohort 3 of CAP 02 Study (ESMO 2025) - No abstract available

Checkpoint inhibition • Metastases • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma

Clinical benefit of camrelizumab (cam) + rivoceranib (rivo) in unresectable hepatocellular carcinoma (uHCC) patients with macrovascular invasion (MVI) and extrahepatic spread (EHS), CARES-310 (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Effectiveness and Safety of Camrelizumab Plus Rivoceranib Combined With TACE With or Without HAIC in First-Line Treatment of Unresectable Hepatocellular Carcinoma (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Neoadjuvant therapy of sequential transcatheter arterial chemoembolization, camrelizumab and apatinib for single large hepatocellular carcinoma (NEO-START): A randomized controlled trial (ESMO 2025) - No abstract available

Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Adebrelimab plus Apatinib and Etoposide in the Treatment of HER2-Negative Breast Cancer Brain Metastasis: A Phase II Study (ESMO 2025) - No abstract available

P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Comparative effectiveness and safety of second-line therapies and dosing regimens for advanced hepatocellular carcinoma: a network meta-analysis. (PubMed, Eur J Gastroenterol Hepatol) - "Brivanib 800 mg once daily (OD) was most effective in terms of ORR [odds ratio (OR) = 7.13, 95% CI = 1.42, 35.88], while apatinib 750 mg QD ranked highest for DCR (OR = 3.92, 95% CI = 1.76, 8.71). Codrituzumab 1600 mg administered every 2 weeks demonstrated the most advantageous health profile, markedly decreasing AEs and instances of grade 3-4 AEs...Cabozantinib 60 mg QD and pembrolizumab 200 mg Q3W arise as the most suitable second-line therapies alternatives for advanced HCC, offering substantial improvements in survival and disease control with manageable adverse effects. These findings support the integration of both targeted and immune therapies in handling of advanced HCC."

HEOR • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Perioperative Camrelizumab plus Rivoceranib in Resectable Hepatocellular Carcinoma (CARES-009): A Randomized, Multicenter, Phase 3 Trial (ESMO 2025) - No abstract available

Clinical • P3 data • Hepatocellular Cancer • Oncology • Solid Tumor

Fuzuloparib (FZPL) monotherapy or in combination with apatinib (APA) as first-line (1L) maintenance therapy in advanced ovarian cancer (OC): final analysis of the FZOCUS-1 trial (ESMO 2025) - No abstract available

Clinical • Combination therapy • Metastases • Monotherapy • Oncology • Ovarian Cancer • Solid Tumor

The U.S. Food and Drug Administration (FDA) has officially disclosed the reasons for withholding approval of HLB’s liver cancer treatment "Rivoceranib" (Business Korea) - "According to industry sources on Sept. 10, the FDA published a Complete Response Letter (CRL) on its website regarding the combination therapy of Rivoceranib and Chinese Hengrui Pharmaceuticals’ immunotherapy drug 'Camrelizumab'. The FDA stated that approval would only be possible if the two drugs were reviewed together....FDA made it clear that standalone approval for Rivoceranib would not be possible as long as Camrelizumab has not received formal approval in the United States. Furthermore, the FDA cited incomplete bioresearch monitoring (BIMO) inspections at some clinical trial sites....HLB...aiming to reapply within this year."

CRL • Hepatocellular Cancer

FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov) - P2 | N=716 | Recruiting | Sponsor: Fudan University | Trial completion date: Sep 2025 ➔ Sep 2028 | Trial primary completion date: Dec 2024 ➔ Dec 2026

Trial completion date • Trial primary completion date • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Negative Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD8 • FOXC1 • HER-2 • PGR

Efficacy and Safety of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study (ASTRO 2025) - No abstract available

Clinical • Combination therapy • P2 data • Hepatocellular Cancer • Oncology • Solid Tumor

Targeting tumor vascular endothelial cells for hepatocellular carcinoma treatment. (PubMed, World J Gastroenterol) - "Recently, Wu et al reported that apatinib, an inhibitor of vascular endothelial growth factor receptor 2, can inhibit tumor VEC glycolysis by regulating phosphatidylinositol 3-kinase/protein kinase B/6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 signaling pathway to suppress HCC progression. With great interest, this editorial paper aims to review the function and key molecular signaling pathways of tumor VECs in HCC initiation and progression and summarize potential treatment options in clinical trials."

Journal • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor • CD8

TASK-05: HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) (clinicaltrials.gov) - P2 | N=45 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Biliary Cancer • Cholangiocarcinoma • Hepatocellular Cancer • Oncology • Solid Tumor

Case Report: Long-term response control in a patient with metastatic gastric squamous cell carcinoma treated with nivolumab and chemoradiotherapy. (PubMed, Front Immunol) - "The patient received nivolumab with oxaliplatin, leucovorin, and fluorouracil plus local radiotherapy as first-line treatment; nivolumab, paclitaxel polymer micelles, and carboplatin as the second-line treatment, and nivolumab and apatinib as the third-line treatment. Genomic and immune characteristics were analyzed to understand the underlying disease mechanisms. In conclusion, integrated therapy (immunotherapy, chemotherapy, local radiotherapy, and anti-angiogenic therapy) may be the ideal treatment approach for patients with GSCC with multiple metastases; however, prospective studies are needed to verify its efficacy."

Journal • Epstein-Barr Virus Infections • Gastric Adenocarcinoma • Gastric Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma

A Single-arm, Multicenter, Exploratory Study of Adebrelimab Combined With Apatinib and Systemic Chemotherapy for Initially Unresectable Biliary Tract Cancer (clinicaltrials.gov) - P2 | N=37 | Recruiting | Sponsor: Yongjun Chen

New P2 trial • Biliary Cancer • Biliary Tract Cancer • Oncology • Solid Tumor

Mesenteric Artery Dissection Aneurysm Associated with Apatinib in a Prostate Cancer Patient: A Case Report and Literature Review. (PubMed, Res Rep Urol) - "As clinicians, it is imperative to remain vigilant against potential complications such as arterial dissection and aneurysm, while conducting meticulous evaluations of associated risks. Notably, this article serves solely as a reference and does not advocate for the adjustment of treatment protocols on this basis."

Journal • Cardiovascular • Gastric Cancer • Genito-urinary Cancer • Oncology • Pain • Prostate Adenocarcinoma • Prostate Cancer • Solid Tumor

Efficacy of Apatinib plus Temozolomide in Treating Recurrent Malignant Brain Glioma. (PubMed, Afr Health Sci) - "Follow-up results showed that the Combination group had a significantly better overall survival (OS) and progression-free survival (PFS) than the Control group. Compared with temozolomide alone, apatinib plus tenozolomide can significantly improve the clinical efficacy in treating recurrent malignant brain glioma, prolong the survival of patients and produce tolerable adverse reactions."

Journal • Retrospective data • Brain Cancer • Cardiovascular • Dermatology • Glioma • High Grade Glioma • Hypertension • Oncology • Renal Disease • Solid Tumor

HCC-IM-1: Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment (clinicaltrials.gov) - P=N/A | N=150 | Not yet recruiting | Sponsor: Fudan University

New trial • Hepatocellular Cancer • Oncology • Solid Tumor

The tumor suppressor DACT3 sensitizes triple-negative breast cancer to apatinib by inhibiting the Wnt/β-catenin pathway. (PubMed, Transl Oncol) - "Furthermore, we explored that the exogenous expression of DACT3 could downregulate the IC50 of apatinib (Vector vs DACT3: 16.04 μM vs 8.81 μM in MDA-MB231 cells, 19.65 μM vs 9.42 μM in YCCB1 cells) by inhibiting the Wnt/β-catenin signaling, a pro-malignancy pathway that leads to apatinib resistance through crosstalk with the VEGF/VEGFR2 pathway. In summary, our results indicate that DACT3 is a potential biomarker for predicting the response to apatinib and a new therapeutic target for improving TNBC sensitivity to apatinib."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

A Study on the Heterogeneity of Efficacy of Interventional Therapy Combined With Systemic Therapy for Liver Cancer Based on Multi-center Real-world Data (clinicaltrials.gov) - P=N/A | N=2000 | Not yet recruiting | Sponsor: Xuhua Duan

Heterogeneity • IO biomarker • New trial • Real-world evidence • Hepatocellular Cancer • Liver Cancer • Oncology • Solid Tumor

The synergistic potential of camrelizumab and rivoceranib in advanced hepatocellular carcinoma: a review of current evidence. (PubMed, Ann Med Surg (Lond)) - "The final analysis of CARES-310 demonstrated a median overall survival (OS) of 23.8 months with camrelizumab plus rivoceranib, significantly higher than the 15.2 months observed with sorafenib (HR, 0.64; 95% CI, 0.52-0.79; P < 0.0001). With a manageable safety profile and significant survival benefits, camrelizumab plus rivoceranib represents a major advancement in HCC treatment. Ongoing research will further define its role in clinical practice and optimize outcomes for patients with limited treatment options."

Journal • Review • Hepatocellular Cancer • Oncology • Solid Tumor

PD-1 Inhibitors Combined With Targeted Therapy With or Without Interventional Therapy for Advanced HCC (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Peking Union Medical College Hospital

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor

SYSKY-2023-1016-01: Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - P3 | N=200 | Recruiting | Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Oncology • Solid Tumor • BRCA

CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - P3 | N=572 | Recruiting | Sponsor: AstraZeneca | Trial completion date: Oct 2026 ➔ Apr 2027 | Trial primary completion date: Apr 2026 ➔ Oct 2026

Monotherapy • Trial completion date • Trial primary completion date • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor